AOD-9604 Evidence Guide
Evidence for AOD-9604 is too preliminary to support a research protocol with confidence. The compound's Phase 3 trial failed on the primary endpoint, returning negative efficacy data for weight loss in humans. Of the Weight Loss & Metabolic compounds in this library, semaglutide, tirzepatide, or retatrutide have vastly stronger evidence bases as starting points.
Our Take
Evidence for AOD-9604 is too preliminary to support a research protocol with confidence. The compound's Phase 3 trial failed on the primary endpoint, returning negative efficacy data for weight loss in humans. Of the Weight Loss & Metabolic compounds in this library, semaglutide, tirzepatide, or retatrutide have vastly stronger evidence bases as starting points.
- Best for
- No validated human application - mechanistic lipolysis research only
- Evidence grade
- Level D
- Confidence
- Low
- Starting point
- No established human protocol - Phase 3 failure precludes a meaningful starting point
Benefits and Evidence
- Fat Mass Reduction: Level D, includes human evidence - Heffernan et al. (2001, Obes Res) reported reduced adiposity in ob/ob mice at 500 mcg/kg/day SC for 14 days; however, a Phase IIb RCT by Metabolic Pharmaceuticals (2007, n=536, 1 mg/day oral, 24 weeks) showed no significant weight loss vs. placebo in obese adults (p=0.53).
- Cartilage Repair: Level D, mostly non-human evidence - Some preclinical evidence suggests potential for cartilage regeneration, leading to investigation as an osteoarthritis treatment in Australia (granted GRAS status by FDA for this use).
Side Effects and Warnings
- Injection site irritation
- Headache
- Mild nausea
- Fatigue
- Not FDA approved for any indication
- Human clinical trials for obesity did not meet primary endpoints
- Quality and purity of research-grade peptides may vary significantly
- Banned by WADA in competitive sports
Research Dosage References
- <strong>Subcutaneous injection</strong> - 250-500 mcg - Once daily - Research dosage used in clinical studies. Typically administered in the morning on an empty stomach.
- <strong>Oral</strong> - 1-5 mg - Once daily - Oral formulations have been explored but bioavailability is limited.
Mechanism of Action
AOD-9604 mimics the lipolytic action of natural growth hormone by interacting with the beta-3 adrenergic receptor pathway in adipose tissue. Unlike full-length growth hormone, it does not bind to the GH receptor and therefore does not stimulate IGF-1 production or promote linear growth. The peptide stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) in adipose tissue through a mechanism believed to involve enhancement of beta-oxidation of fatty acids. Preclinical studies in obese animal models demonstrated significant reductions in body fat without changes in lean mass or food intake. Importantly, AOD-9604 does not appear to affect blood glucose levels or insulin sensitivity, distinguishing it from exogenous growth hormone administration which can cause insulin resistance and hyperglycemia.
Legal Status
Not FDA approved. Available as a research chemical in some jurisdictions. GRAS status granted by FDA for use in food supplements in specific contexts. Banned by WADA.
Primary Sources
- Metabolic effects of the fat-reducing peptide AOD-9604 in obese Zucker rats. Obesity Research, 2001.
- A double-blind placebo-controlled study of AOD-9604 in obese subjects. International Journal of Obesity, 2004.